NASDAQ:RLYB Rallybio (RLYB) Stock Price, News & Analysis $1.36 +0.03 (+2.26%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$1.33▼$1.3850-Day Range$1.20▼$1.7152-Week Range$1.16▼$6.33Volume66,115 shsAverage Volume841,788 shsMarket Capitalization$56.37 millionP/E RatioN/ADividend YieldN/APrice Target$12.20 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Rallybio alerts: Email Address Rallybio MarketRank™ Stock AnalysisAnalyst RatingModerate Buy2.67 Rating ScoreUpside/Downside797.1% Upside$12.20 Price TargetShort InterestHealthy2.61% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.44Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.42) to ($1.18) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.60 out of 5 starsMedical Sector283rd out of 936 stocksPharmaceutical Preparations Industry129th out of 436 stocks 3.3 Analyst's Opinion Consensus RatingRallybio has received a consensus rating of Moderate Buy. The company's average rating score is 2.67, and is based on 4 buy ratings, 2 hold ratings, and no sell ratings.Amount of Analyst CoverageRallybio has only been the subject of 2 research reports in the past 90 days.Read more about Rallybio's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted2.61% of the float of Rallybio has been sold short.Short Interest Ratio / Days to CoverRallybio has a short interest ratio ("days to cover") of 2.5, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Rallybio has recently decreased by 57.56%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldRallybio does not currently pay a dividend.Dividend GrowthRallybio does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RLYB. Previous Next 3.6 News and Social Media Coverage News SentimentRallybio has a news sentiment score of 1.44. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Rallybio this week, compared to 1 article on an average week.Search Interest1 people have searched for RLYB on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Rallybio to their MarketBeat watchlist in the last 30 days. This is a decrease of -67% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Rallybio insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 7.40% of the stock of Rallybio is held by insiders.Percentage Held by Institutions90.34% of the stock of Rallybio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Rallybio's insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Rallybio are expected to grow in the coming year, from ($1.42) to ($1.18) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Rallybio is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Rallybio is -0.72, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRallybio has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Rallybio's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Rallybio Stock (NASDAQ:RLYB)Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT. The company is also developing RLYB114, a pegylated complement factor 5 (C5)-targeted Affibody molecule in preclinical development for the treatment of complement-mediated ophthalmic diseases; RLYB116, an inhibitor of complement component 5 (C5) to treat several diseases of complement dysregulation which has completed phase 1 trial; and RLYB331, a preclinical antibody, for the treatment of severe anemia with ineffective erythropoiesis and iron overload. It entered into a strategic alliance with AbCellera to discover, develop, and commercialize novel antibody-based therapeutics for rare diseases. Rallybio has collaboration with Exscientia for the development of small molecule therapeutics for rare diseases; and collaboration agreement with Johnson & Johnson to provide pregnant individuals therapeutic solutions at risk of fetal and neonatal alloimmune thrombocytopenia. The company was founded in 2018 and is headquartered in New Haven, Connecticut.Read More RLYB Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RLYB Stock News HeadlinesJune 17, 2024 | businesswire.comRallybio Announces Results of Epidemiological Analysis Demonstrating FNAIT Risk Across Racially and Ethnically Diverse PopulationsMay 31, 2024 | investorplace.com3 Sorry Biotech Stocks to Sell in May While You Still CanJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.May 16, 2024 | msn.comJP Morgan Downgrades Rallybio (RLYB)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio: Promising FNAIT Drug Candidate and Strong FinancialsMay 10, 2024 | markets.businessinsider.comRallybio’s Advancements and Financial Health Prompt a Buy Rating from Analyst Jonathan WollebenMay 9, 2024 | finance.yahoo.comRallybio Reports First Quarter 2024 Financial Results and Provides Business UpdatesMay 7, 2024 | finance.yahoo.comRallybio to Present at the 2024 Citizens JMP Life Sciences ConferenceJuly 27, 2024 | Paradigm Press (Ad)Musk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just released the details on what he’s calling Elon’s Project X-9840.April 23, 2024 | finance.yahoo.comFibroGen, Inc. (FGEN)April 18, 2024 | markets.businessinsider.comBuy Rating Affirmed for Rallybio Amid Significant Market Opportunity in FNAIT TreatmentApril 17, 2024 | msn.comRallybio (RLYB) Price Target Decreased by 16.00% to 12.85April 17, 2024 | businesswire.comFNAIT Systematic Literature Review and Meta-Analysis Presented at the Academy of Managed Care Pharmacy 2024 Annual MeetingApril 14, 2024 | finance.yahoo.comCozad New Venture Challenge Demo Day awards student start-ups with fundingApril 12, 2024 | investing.comRallybio partners with Johnson & Johnson on FNAIT treatmentApril 11, 2024 | msn.comRare Disease-Focused Rallybio Inks Development Pact With Johnson & Johnson, Stock Shoots HigherApril 11, 2024 | proactiveinvestors.comRallybio partners with J&J to advance therapies targeting rare fetal diseaseApril 11, 2024 | msn.comRallybio shares gain on investment from J&J for rare fetal condition treatmentSee More Headlines Receive RLYB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Rallybio and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today7/26/2024Next Earnings (Estimated)8/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RLYB CUSIPN/A CIK1739410 Webwww.rallybio.com Phone203-59-3820FaxN/AEmployees40Year FoundedN/APrice Target and Rating Average Stock Price Target$12.20 High Stock Price Target$18.00 Low Stock Price Target$8.00 Potential Upside/Downside+810.4%Consensus RatingModerate Buy Rating Score (0-4)2.67 Research Coverage6 Analysts Profitability EPS (Most Recent Fiscal Year)($1.88) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-74,560,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-66.59% Return on Assets-61.54% Debt Debt-to-Equity RatioN/A Current Ratio9.77 Quick Ratio9.77 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$2.81 per share Price / Book0.48Miscellaneous Outstanding Shares41,450,000Free Float38,382,000Market Cap$55.54 million OptionableNot Optionable Beta-1.69 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. Martin W. MacKay Ph.D. (Age 68)Co-Founder & Executive Chairman Comp: $723.35kDr. Stephen Uden M.B (Age 66)M.D., Co-Founder, President, CEO & Director Comp: $723.35kMr. Jonathan I. Lieber M.B.A. (Age 54)CFO & Treasurer Comp: $667.13kDr. Steven W. Ryder F.A.C.P (Age 72)M.D., Chief Medical Officer Comp: $680.22kKey CompetitorsLeap TherapeuticsNASDAQ:LPTXMagenta TherapeuticsNASDAQ:MGTACardiff OncologyNASDAQ:CRDFCytomX TherapeuticsNASDAQ:CTMXShattuck LabsNASDAQ:STTKView All CompetitorsInstitutional OwnershipVanguard Group Inc.Bought 12,801 shares on 5/10/2024Ownership: 2.848%Acadian Asset Management LLCBought 31,294 shares on 5/10/2024Ownership: 0.083%View All Institutional Transactions RLYB Stock Analysis - Frequently Asked Questions How have RLYB shares performed this year? Rallybio's stock was trading at $2.39 at the start of the year. Since then, RLYB shares have decreased by 43.1% and is now trading at $1.36. View the best growth stocks for 2024 here. How were Rallybio's earnings last quarter? Rallybio Co. (NASDAQ:RLYB) announced its quarterly earnings results on Thursday, May, 9th. The company reported ($0.47) earnings per share for the quarter, beating analysts' consensus estimates of ($0.50) by $0.03. When did Rallybio IPO? Rallybio (RLYB) raised $80 million in an IPO on Thursday, July 29th 2021. The company issued 5,750,000 shares at $13.00-$15.00 per share. How do I buy shares of Rallybio? Shares of RLYB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RLYB) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rallybio Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rallybio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
